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sis of discharge data to compare find-
ings from the United States with data
from Germany. We therefore deter-
mined the absolute number of inpa-
tient discharges from all hospitals in
Germany with the number of dis-
charge diagnoses of CDAD reported
in the national Statistische Bundesamt
for the years 2000–2004. We then cal-
culated the incidence of CDAD as a
discharge diagnosis for each year and
stratified our results by age groups
(Figure). 
Our results confirm the observa-
tions from the United States. The
effect of C. difficile on illness of
patients in hospitals in Germany has
escalated dramatically. This is true
especially for patients >60 years of
age. This trend indicates the need for
increased awareness of this pathogen
and a concerted effort to control
CDAD by reducing unnecessary
antimicrobial drug use and imple-
menting currently recommended
infection control measures. It also
highlights the need to develop more
rapid and accurate diagnostic tools
and more effective prevention and
treatment strategies.
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Human Bocavirus
in Febrile Children,
the Netherlands 
To the Editor: Human bocavirus
(HBoV) is a recently discovered virus
of the family Parvoviridae, genus
Bocavirus, which appears to cause
widespread respiratory tract infec-
tions (RTI) in children. In selected
groups of children with RTI, detection
rates have varied from 2.8% to 11.3%
(1–9). However, the exact prevalence
and pathogenic effects of this virus
remain to be established.
During a prospective cohort
study to evaluate the prognosis of
fever at a general practice after-hours
service in Rotterdam, nasopharyngeal
swabs were collected from febrile
children and tested for respiratory
viruses, including HBoV. We report
the incidence and clinical features of
HBoV infection in these children.
From June 1, 2005, through
January 16, 2006, all children 3
months to 6 years of age whose par-
ents contacted the after-hours service
because of fever, as reported by par-
ents and not further defined, were eli-
gible for inclusion in the study.
Children were excluded when the par-
ents could not communicate in Dutch
(n = 77) and if the child had already
been included within the past 2 weeks
(n = 11). A research nurse visited the
child at home within 24 hours of
inclusion. The child was physically
examined, and a nasopharyngeal swab
and a blood sample for C-reactive
protein measurement were collected.
The parents subsequently recorded
the child’s symptoms in a diary for 7
days. The Central Committee on
Research Involving Human Subjects,
the Netherlands, approved this study.
Nucleic acids were isolated on a
MagnaPure isolation station (Roche
Applied Science, Penzberg, Germany)
and subsequently analyzed by real-
time assays. Detection of HBoV was
performed by using a primers set and a
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Figure. Incidence of Clostridium difficile–associated disease per 100,000 inpatients upon
discharge from hospitals in Germany.LETTERS
fluorescein amadite–labeled TaqMan
probe directed against sequences of
the NP1 gene. (Sequences are avail-
able from the corresponding author.)
Testing was routinely done for the fol-
lowing viruses: influenza virus types
A and B, parainfluenza virus types
1–4, respiratory syncytial virus (RSV)
types A and B, adenovirus, coron-
avirus (OC43, 229E, and NL63), and
rhinovirus.
Nasopharyngeal swabs were col-
lected from 257 (81%) of 319 enrolled
children. The overall virus detection
rate was 52.9%; most frequently
detected were adenovirus (11%),
RSV-A (10.5%), parainfluenza virus
type 1 (8.5%), and rhinovirus (8%).
Five children were included twice;
none of them was HBoV positive. The
PCR for HBoV was positive in 4 chil-
dren (1.6%), all boys. The characteris-
tics of these children are shown in the
Table.
All 4 children reported rhinorrhea
and cough. Patient 1 reported abdom-
inal pain, diarrhea (more than twice
daily, with mucus), dyspnea, and a
skin rash, along with respiratory
symptoms. All symptoms lasted for
>1 week. At physical examination, the
research nurse evaluated the children
to be not ill or (slightly) ill, based on
standard criteria. Patient 1 had a skin
rash and palpable cervical lymph
nodes. Patient 4 had palpable lymph
nodes and red tonsils.
Patient 1 was given amoxicillin
for otitis media, and patient 4 received
amoxicillin for tonsillitis, as diag-
nosed by the general practitioner on
the basis of the patient’s clinical
symptoms, without bacteriologic con-
firmation. During a 1-week follow-up
period, none of the patients sought
further medical advice.
Our finding that HBoV may
cause RTI is in accordance with the
literature (1–6). Our findings support
those of others in suggesting a role for
HBoV in systemic infection, causing
gastrointestinal symptoms and skin
rash (6,8).
Our detection rate, in general
practice, is lower than the rates report-
ed from former studies of children
with RTI (3%–10%) (1–8).
Coinfection of HBoV and other virus-
es was found among 3 (75%) of 4
children (Table). In other studies,
coinfection was found in
17.6%–55.6% (mainly adenovirus,
RSV, and human metapneumovirus)
(1,2,5,7–9). The other detected virus-
es could have caused the symptoms of
patients 2–4. However, HBoV was the
only detected virus in 1 child with res-
piratory symptoms, gastrointestinal
symptoms, and rash, and therefore
might be the pathogen. Considering
the high amount of HBoV in patient 3,
symptoms were likely caused by
HBoV in this patient as well.
Our ability to analyze severity of
disease in our study population was
limited because all children had mild
disease, and no child was hospital-
ized. However, all children reported a
prolonged course of fever, >7 days or
recurrent within 1 week. This finding
is in contrast with the mean duration
of fever of 2.6 days in the study of
Arnold et al., which was based in a
hospital setting (6). In our study, none
of the HBoV-positive children
received a diagnosis of bronchiolitis,
pneumonia, or bronchitis, as in previ-
ous studies. None of the 4 children in
our study was born preterm, com-
pared with 19%–44% of HBoV-posi-
tive children in previous studies (5,6).
None had a positive history for asth-
ma or other underlying diseases, as
did up to 50% of the children in previ-
ous studies (1,6).
In conclusion, HBoV was detect-
ed in nasopharyngeal swabs of 4
(1.6%) of 257 children <6 years of
age whose parents contacted a gener-
al practice after-hours service. Our
results suggest that HBoV might
cause mild disease with respiratory
and gastrointestinal symptoms and
skin rash. Further research, not
restricted to susceptible or hospital-
ized patients, is needed to clarify the
prevalence and pathogenicity of this
new virus in the general population.
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Dengue Virus
Serotype 3,
Karachi, Pakistan
To the Editor: The global preva-
lence of dengue fever (DF) has grown
dramatically in recent decades; DF is
now endemic to >100 countries (1).
Dengue hemorrhagic fever (DHF), a
potentially lethal complication of
dengue virus infection, was first rec-
ognized in Asia in the 1950s and is
now a leading cause of hospitalization
and death among children (1). During
the past decade, DHF epidemics have
occurred in China, Sri Lanka, India,
the Maldives, Bangladesh, and
Pakistan (2–4).
In Pakistan, an outbreak of DHF
was first reported in Karachi in 1994
(4). Through mid-2005, 15–20
patients with DF or DHF were admit-
ted each year to the Aga Khan
University Hospital (AKUH), a terti-
ary care referral center in Karachi.
Many more cases, however, may have
gone unrecognized. Ours is the first
report of dengue virus serotype 3 in
Pakistan.
From September through
December 2005, at least 3 major hos-
pitals in Karachi, including AKUH,
had a sudden increase in the number
of patients with signs consistent with
the World Health Organization defi-
nition of DHF: high fever, rash, epis-
taxis, gum bleeding, liver dysfunc-
tion, and thrombocytopenia (platelets
<100,000/mm3); most had evidence
of capillary leakage in the form of
raised hematocrit and pleural effusion
with or without ascites (5). Because
in Pakistan, Crimean-Congo hemor-
rhagic fever (CCHF) is an important
differential diagnosis for hemorrhag-
ic fever, most patients seen at AKUH
received care in strict isolation and
were empirically treated with rib-
avirin. At time of admission, blood
samples were collected for serologic
testing for dengue virus and reverse
transcription (RT)–PCR testing for
CCHF virus. The first 5 samples, col-
lected during the initial 2 weeks of
the outbreak, were also sent to the
Special Pathogens Reference Unit,
Centre for Emergency Preparedness
and Response, Health Protection
Agency, Salisbury, United Kingdom,
for diagnostic confirmation. In the
absence of a local surveillance and
disease notification system, the num-
ber of patients with suspected DHF at
different hospitals in Karachi could
not be ascertained.
Of the 106 patients who had a
clinical diagnosis compatible with
DHF (5), 9 (8.5%) died and 97
(91.5%) recovered. Patients with pos-
sible DF (fever, mild thrombocytope-
nia with platelets >100,000/mm3)
were not admitted and were treated as
outpatients. Dengue virus infection
was confirmed for 42 of the 106
patients. Serum samples from 39
patients contained anti–dengue virus
immunoglobulin M (IgM) antibody
(Chemicon, Temecula, CA, USA).
Diagnosis for 6 of these patients was
confirmed by using immunoblot tests
(Dengue IgM Blot and Dengue IgG
Blot, Genelabs Diagnostics,
Singapore). Of the 9 patients who
died, 6 had dengue IgM and IgG
according to immunoblot testing, and
3 had dengue IgM according to
ELISA. Diagnoses for 3 additional
patients were confirmed by RT-PCR.
An RT-PCR assay specific for
dengue viruses (6) was used to ampli-
fy the C/PrM/M region of the genome
and produced PCR products of the
expected size in 3 patient samples: 2
(K1 and 2) from Karachi and 1 (B)
from Balochistan. The PCR products
were sequenced, and data were subse-
quently placed in GenBank under
accession numbers DQ469827 for
D3418-05 (patient K1), DQ469828
for D3419-05 (patient K2), and
DQ469826 for D3417-05 (patient B).
These data were compared with those
in databases by using the basic local
alignment search tool for nucleotides
(blastn), with default settings (7). For
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